Max Robotics — Global Service Robot Directory + US Certification

About

Masahiko Kubo is a leading surgical oncologist whose research focuses on advanced gastric and gastroesophageal junction cancers, with particular expertise in targeted therapies and minimally invasive surgical techniques. His most impactful work centers on zolbetuximab-based chemotherapy for CLDN18.2-positive tumors, where he has documented both therapeutic efficacy and critical adverse events—including the first reported cases of protein-losing enteropathy induced by this novel antibody (2025, 13 citations). Kubo’s contributions extend to comparative surgical outcomes, as demonstrated in his study of robotic versus laparoscopic gastrectomy, which provides three-year survival data and perioperative performance metrics (2025, 10 citations). He has also pioneered conversion surgery following zolbetuximab-based regimens, offering new hope for patients with initially unresectable disease (2025, 2 citations). By bridging real-world clinical observations with rigorous outcome analysis, Kubo’s work directly informs treatment protocols for HER2-negative, CLDN18.2-positive advanced gastric cancer. His research is essential reading for oncologists and surgeons navigating the evolving landscape of targeted therapy and minimally invasive gastrectomy.